XAF genes and polypeptides: methods and reagents for modulating apoptosis
AssigneeAegera Therapeutics, Inc.
InventorsRobert G. Korneluk, Katsuyuki Tamai, Peter Liston, Alexander E. MacKenzie
Life of this patent
Estimating the term…
Abstract
The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
Claims12
A method of identifying a compound that modulates apoptosis, said method comprising:
- (a) providing a cell comprising a XAF gene;
- and
- (b) contacting said cell with a candidate compound;
- and
- (c) monitoring expression of said AAF gene, an alteration in the level of expression of said gene indicating a compound which modulates apoptosis.
A method of identifying a compound that modulates apoptosis, said method comprising:
- (a) providing a cell comprising a reporter gene operably linked to a promoter from a XAF gene;
- (b) contacting said cell with a candidate compound;
- and
- (c) measuring expression of said reporter gene, an alteration in said expression in response to said candidate compound identifying a compound that is able to modulate apoptosis.
A method of identifying a compound that is able to inhibit XAF-mediated apoptosis, said method comprising the steps of:
- (a) providing a cell expressing an apoptosis-inducing amount of XAF;
- (b) contacting said cell with a candidate compound;
- and
- (c) measuring level of apoptosis in said cell, a decrease in said level relative to a level in a cell not contacted with said candidate compound indicating a compound that able to inhibit XAF-mediated apoptosis.
A method of identifying a compound that is able to induce XAF-mediated apoptosis, said method comprising the steps of:
- (a) providing a cell expressing an apoptosis-inducing amount of XAF;
- (b) contacting said cell with a candidate compound;
- and
- (c) measuring level of apoptosis in said cell, an increase in said level relative to a level in a cell not contacted with said candidate compound indicating a compound that able to induce XAF-mediated apoptosis.
A method of identifying a compound that modulates apoptosis, said method comprising:
- (a) providing a cell expressing a TRAF polypeptide, a XAF polypeptide, and a reporter gene operably linked to DNA comprising an NF-κB binding site;
- (b) contacting said cell with a candidate compound;
- and
- (c) measuring expression of said reporter gene, a change in expression in response to said compound indicating said compound is able to modulate apoptosis.
A method of identifying a compound that modulates apoptosis, said method comprising:
- (a) providing a cell expressing a TRAF polypeptide, a XAF polypeptide, an IAP polypeptide, and a reporter gene operably linked to DNA comprising an NF-κB binding site;
- (b) contacting said cell with a candidate compound;
- and
- (c) measuring expression of said reporter gene, a change in expression in response to said compound indicating said compound is able to modulate apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing a cell having:
- (i) a reporter gene operably linked to a DNA-binding-protein recognition site;
- (ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising a XAF polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
- (iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising a second XAF polypeptide covalently bonded to a gene activating moiety;
- (b) exposing said cell to said compound;
- and
- (c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing a cell having:
- (i) a reporter gene operably linked to a DNA-binding-protein recognition site;
- (ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising a XAF polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
- (iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising an IAP polypeptide covalently bonded to a gene activating moiety;
- (b) exposing said cell to said compound;
- and
- (c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing a cell having:
- (i) a reporter gene operably linked to a DNA-binding-protein recognition site;
- (ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising an IAP polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
- (iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising a XAF polypeptide covalently bonded to a gene activating moiety;
- (b) exposing said cell to said compound;
- and
- (c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing a first XAF polypeptide, said first XAF polypeptide immobilized on a solid-phase substrate;
- (b) contacting said first XAF polypeptide with a second XAF polypeptide;
- (c) contacting said first XAF polypeptide and said second XAF polypeptide with a compound;
- and
- (d) measuring amount of binding of said first XAF polypeptide to said second XAF polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing a XAF polypeptide, said XAF polypeptide immobilized on a solid-phase substrate;
- (b) contacting said XAF polypeptide with an TAP polypeptide;
- (c) contacting said XAF polypeptide and said TAP polypeptide with a compound;
- and
- (d) measuring amount of binding of said XAF polypeptide to said TAP polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.
A method for detecting a compound capable of modulating apoptosis, said method comprising:
- (a) providing an TAP polypeptide, said TAP polypeptide immobilized on a solid-phase substrate;
- (b) contacting said IAP polypeptide with a XAF polypeptide;
- (c) contacting said IAP polypeptide and said XAF polypeptide with a compound;
- and
- (d) measuring amount of binding of said IAP polypeptide to said XAF polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.
Dependencies are inferred from the claim text.